I always get excited by plenaries at major conferences. Today’s DeLLphi-305 results are an example of seeing the standard of care changing to better patients’ lives. Tarlatamab is

Anthony Serritella· @aserritella1984 · X·2026-10-25 03:13· 11 hours agoScore70

Body · original

I always get excited by plenaries at major conferences. Today’s DeLLphi-305 results are an example of seeing the standard of care changing to better patients’ lives. Tarlatamab is finding its most exiting “moment” in MRD-low disease maintenance #ESMO26 #Tarlatamab

105 views · 4 likes · 1 repost · 0 replies

Conference abstracts

LBA3matched by Presidential Symposium I

Tarlatamab plus durvalumab (durva) vs durva as 1L maintenance (1LM) therapy following durva, platinum, and etoposide (1L durva + EP) in extensive-stage small cell lung cancer (ES-SCLC): Primary analysis of the phase 3 DeLLphi-305 trial

https://esmocongress.esmo.org

Source: Anthony Serritella · x.com